🆕 We’re thrilled to unveil our Special Issue on Personalised Dermatology!
📖 This March, JEADV dives into the evolving world of personalised dermatology, exploring the latest research and clinical advances tailored to individual patient care.
✨ For this special occasion, we’re also introducing a brand-new cover format: a fresh look for an exciting milestone!
🔗 Read more at the link in bio
#dermatology #dermatologist #venereology #venereologist #medicine #jeadv #eadv #PersonalisedDermatology
📣 𝗝𝗘𝗔𝗗𝗩 𝗖𝗮𝗹𝗹 𝗳𝗼𝗿 𝗣𝗮𝗽𝗲𝗿𝘀 | 𝗛𝗶𝗱𝗿𝗮𝗱𝗲𝗻𝗶𝘁𝗶𝘀 𝗦𝘂𝗽𝗽𝘂𝗿𝗮𝘁𝗶𝘃𝗮
JEADV invites clinically focused submissions for a Special Issue on Hidradenitis Suppurativa, guest edited by Prof. Thrasyvoulos Tzellos and Prof. Francesca Prignano, addressing unmet needs in diagnosis, treatment, and patient care.
🧠 Topics include new therapies, personalized medicine, imaging, AI, comorbidities, patient perspectives, and more.
🗓️ Submission deadline: 31 May 2026
🔗 Full information via link in bio
Join us in advancing care and awareness in HS.
#JEADV #HidradenitisSuppurativa #Dermatology #CallForPapers #ClinicalResearch #SpecialIssue #EADV
Time for Editor's Pick 2️⃣!
Our Editor-in-Chief, Prof. Carle Paul, spotlights an important study by Fotheringham et al. on in situ and localized primary invasive pregnancy-associated melanoma.
Pregnancy-associated melanoma occurs during pregnancy or within 12 months postpartum, and while some studies suggest increased mortality, population-based analyses show comparable survival to non-pregnant women. This article examines maternal and perinatal outcomes in early-stage PAM, offering crucial insights for clinicians navigating diagnosis, counseling, and management in this unique patient population.
👀 Watch the video to learn how to optimize care for women with #PAM.
📖 Read more: link in bio #Dermatology #Melanoma #PregnancyAssociatedMelanoma#SkinCancer #ClinicalDermatology
🎯 It’s #JEADVWeeklyQuiz time!
A 52-year-old woman receiving rituximab and chronic corticosteroids presents with indurated violaceous plaques with central non-healing ulcerations on the ankle 🦶💉
Skin biopsy shows suppurative inflammation with characteristic morula-like structures in the dermis, and culture reveals sporangia containing endospores 🧫
Which pathogen is the most likely cause of this cutaneous infection?
A) Sporothrix schenckii
B) Mycobacterium marinum
C) Prototheca wickerhamii
D) Nocardia brasiliensis
E) Blastomyces dermatitidis
💬 Credit to @mohamadgoldust for this insight
#CutaneousProtothecosis #Rituximab #Dermatology #InfectiousDiseases #Immunosuppression #SkinHealth
🧬 Early Gene Therapy for Infantile Dystrophic Epidermolysis Bullosa
Dystrophic epidermolysis bullosa (DEB) is a devastating inherited blistering disorder caused by mutations in COL7A1, leading to defective collagen VII and fragile skin.
In the Letter to the Editor, Karakioulaki et al. report the successful use of beremagene geperpavec (B-VEC) in an infant with severe recessive DEB.
🔎 Key highlights:
• Weekly topical B-VEC gene therapy led to healing of chronic wounds within 26 weeks
• Acute wounds healed in <7 days with minimal scarring
• The infant showed improved growth, reduced inflammation, and discontinuation of morphine
• Treatment was well tolerated with no reported adverse effects
These real-world observations suggest that early initiation of B-VEC may significantly improve outcomes in infants with severe DEB, highlighting the transformative potential of topical gene therapy in dermatology.
📖 Read the article by Karakioulaki et al. at the link in bio.
👏 Shoutout to @mohamadgoldust for sharing this!
#JEADV #Dermatology #EpidermolysisBullosa #GeneTherapy #RareDiseases #DermResearch #PediatricDermatology
Wishing all nurses, and especially dermatology nurses, a fantastic International Nurses Day.
Looking ahead to connecting at the next EADV Congress in Vienna (30 September–3 October), an opportunity to exchange knowledge, share experiences, and grow together within the EADV Nurse community.
The EADV Nurse Task Force session will take place as a subspecialty session titled “European Dermatology Nurse Task Force” on Wednesday 30 September 📅 from 10:15 to 11:45 CEST ⌚.
Further details will be available in the Scientific Programme.
Know more in the LINK IN BIO ➡️ Congress 2026
#EADVCongress #NursesDay
👀 Watch the video to discover key insights on upadacitinib in atopic dermatitis!
In this update by Bunick et al, learn about the long-term safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis.
💊 This once-daily JAK1 inhibitor shows important data on tolerability, adverse events, and chronic disease management over 6 years.
📖 Full article at the link in bio.
#Dermatology #AtopicDermatitis #Eczema #JAKInhibitor #Upadacitinib #SkinHealth
Lupus can affect more than the skin, but its visible signs are often where awareness begins. A rash after mild sun exposure or fingers turning white/blue in the cold could be signs of Systemic Lupus Erythematosus.
Lupus is more than skin. It can affect multiple organs and early signs matter. By increasing understanding and encouraging vigilance, we can support those affected and contribute to earlier detection, improved care, and better outcomes.
If in doubt, consult your dermatologist.
#LupusAwareness #ListenToYourSkin #WorldLupusDay #EADV
A productive morning with the JEADV Editorial Team during the EADV Symposium in Athens.
The meeting offered a valuable moment to reflect, align, and continue strengthening JEADV’s role within the international dermatology and venereology landscape.
Editor-in-Chief @profcarlepaul joined Associate Editors, Section Editors, and Junior Editors for insightful discussions, collaborative planning, and updates across the journal’s activities.
Many thanks as well to the colleagues who participated remotely, and to the Junior Editors for their engaging presentations and contributions to the discussion.
#Dermatology #Venereology #JEADV #EADV #EADVSymposium
🎉 It's Friday and it's time for the first Editor's Pick!
This week, Prof. Carle Paul, our Editor-in-Chief, highlights a must-read article by Fattore et al. on the prevention and management of cutaneous immune-related adverse events.
Immune checkpoint inhibitors are transforming cancer care, but dermatologic toxicities are among the most common immune-related adverse events. This Task Force statement reviews risk factors and offers evidence-based strategies to prevent and manage cirAEs, helping clinicians reduce their impact on patients’ lives.
👀 Watch the video for key insights and discover practical tips for cirAE management.
📖 Learn more: link in bio #Dermatology #SkinHealth #ClinicalDermatology
🎯 It’s #JEADVWeeklyQuiz time!
A man in his 50s presents with chronic swelling and tenderness of the distal interphalangeal joints and periungual areas of the hands for 5 years, worsening in cold weather and improving with warming.
Skin biopsy reveals diffuse dermal lymphocytic infiltration, and immunohistochemistry shows positivity for CD20, CD79a, CD19, CD22, and Bcl-2, with low Ki-67 (<5%) and negativity for CD3, CD4, CD5, CD7, CD8, CD10, Bcl-6, and Cyclin D1 🤲🏻
🧐 Which diagnosis best explains these findings?
A) Cutaneous T-cell lymphoma (mycosis fungoides)
B) Primary cutaneous marginal zone B-cell lymphoma
C) Extranodal NK/T-cell lymphoma
D) Kaposi sarcoma
E) Chronic paronychia
🌟 Thanks @mohamadgoldust for the challenge!
#CutaneousLymphoma #BCellLymphoma #SkinOncology #ClinicalDermatology #SkinHealth #JEADV #Dermatology
🧪 Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in an open-label extension study by Augustin et al.
Atopic dermatitis is a chronic, relapsing, itch-driven neuroimmune disease, so durable, long-term control matters. In the ARCADIA long-term extension study, Augustin et al. report 2-year (Week 104) safety and sustained efficacy outcomes of nemolizumab (anti–IL-31RA) in adolescents and adults with moderate-to-severe AD.
📌 Highlights from the article:
• Large global LTE cohort: 1,901 patients (≥12 years) followed up to 200 weeks (interim results to Week 104)
• Sustained skin clearance: at Week 104, IGA 0/1 ~60% (62.6% PNE; 58.2% NNE)
• Robust clinical response: EASI-75 ~85–88% at Week 104 (88.2% PNE; 85.4% NNE)
• Meaningful symptom relief: itch improvement ≥4 points in ~82–87% and sleep improvement in ~69–71% by Week 104
• Reassuring long-term tolerability: most TEAEs were mild/moderate; common events included COVID-19, nasopharyngitis, URTI, headache, asthma
💡This long-term dataset supports nemolizumab as a durable option targeting the itch pathway (IL-31 signaling) with sustained improvements in signs, symptoms, sleep, and quality of life.
🔗 /10.1111/jdv.70080
🙏 Content by @mohamadgoldust
#JEADV #AtopicDermatitis #Eczema #Pruritus #IL31 #Nemolizumab #Biologics #ClinicalTrials #PatientReportedOutcomes #Dermatology
